Key Takeaways CLB stock sank 21.6% in six months, underperforming its sector, sub-industry and key competitors Q1 revenues and earnings fell YoY and QoQ, driven by sanctions, seasonal slowdowns and weak U.S. activity. Margin pressure, limited growth drivers and high debt levels add to investor concerns about future returns. Core Laboratories Inc. (CLB) has seen a sharp downturn over the past six months, with its share price dropping 21.6%. This decline outpaced the broader oil and energy sector's modest 1 ...